Baird Downgrades Synageva BioPharma (GEVA) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. IVBIY

Go back to Baird Downgrades Synageva BioPharma (GEVA) to Neutral

Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases

May 6, 2015 6:39 AM EDT

-- Expands Alexions metabolic franchise with the addition of Kanuma (sebelipase alfa) for LAL Deficiency (LAL-D) --

-- Launches of Kanuma and Alexions Strensiq (asfotase alfa) expected in 2015 --

-- Creates the most robust rare disease pipeline in biotech; adds SBC-103 for MPS IIIB to clinical development programs --

-- Combined pipeline to have eight highly innovative product candidates in the clinic for eleven indications --

-- Preclinical pipeline to have more than 30 diverse programs across a range of therapeutic... More